Arnethea L Sutton1, Ashley S Felix2, Dipankar Bandyopadhyay3, Reuben Retnam3, William G Hundley4, Vanessa B Sheppard5,6. 1. Department of Health Behavior and Policy, School of Medicine, Virginia Commonwealth University, P.O. Box 980149, Richmond, VA, 23219, USA. Arnethea.sutton@vcuhealth.org. 2. Division of Epidemiology, College of Public Health, The Ohio State University, Columbus, OH, USA. 3. Department of Biostatistics, Virginia Commonwealth University School of Medicine, Richmond, VA, USA. 4. Department of Internal Medicine, Division of Cardiovascular Medicine, Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA. 5. Department of Health Behavior and Policy, School of Medicine, Virginia Commonwealth University, P.O. Box 980149, Richmond, VA, 23219, USA. 6. Office of Health Equity and Disparities Research, Massey Cancer Center, Richmond, VA, USA.
Abstract
PURPOSE: Racial disparities in cardiovascular disease and cardiac dysfunction exist amongst breast cancer survivors. This study examined the prevalence of cardioprotective medication use in survivors and identified factors associated with use by race. METHODS: The analysis included women enrolled in the Women's Hormonal Initiation and Persistence study, a longitudinal observational trial of breast cancer survivors. The study outcome, angiotensin converting enzyme inhibitor (ACEi) or ß-Blocker (BB) use, were ascertained from pharmacy records. Demographic, psychosocial, healthcare, and quality of life factors were collected from surveys and clinical data were abstracted from medical records. Bivariate associations by race and ACEi/BB use were tested using chi square and t tests; logistic regression evaluated multivariable-adjusted associations. RESULTS: Of the 246 survivors in the sample, 33.3% were Black and most were < 65 years of age (58.4%). Most survivors were hypertensive (57.6%) and one-third received ACEi/BBs. In unadjusted analysis, White women (vs. Black) (OR 0.33, 95% 0.19-0.58) and women with higher ratings of functional wellbeing (OR 0.94, 95% 0.89-0.99) were less likely to use ACEi/BBs. Satisfaction with provider communication was only significant for White women. In multivariable-adjusted analysis, ACEi/BB use did not differ by race. Correlates of ACEi/BB use included hypertension among all women and older age for Black women only. CONCLUSIONS: After adjusting for age and comorbidities, no differences by race in ACEi/BB use were observed. Hypertension was a major contributor of ACEi/BB use in BC survivors.
PURPOSE: Racial disparities in cardiovascular disease and cardiac dysfunction exist amongst breast cancer survivors. This study examined the prevalence of cardioprotective medication use in survivors and identified factors associated with use by race. METHODS: The analysis included women enrolled in the Women's Hormonal Initiation and Persistence study, a longitudinal observational trial of breast cancer survivors. The study outcome, angiotensin converting enzyme inhibitor (ACEi) or ß-Blocker (BB) use, were ascertained from pharmacy records. Demographic, psychosocial, healthcare, and quality of life factors were collected from surveys and clinical data were abstracted from medical records. Bivariate associations by race and ACEi/BB use were tested using chi square and t tests; logistic regression evaluated multivariable-adjusted associations. RESULTS: Of the 246 survivors in the sample, 33.3% were Black and most were < 65 years of age (58.4%). Most survivors were hypertensive (57.6%) and one-third received ACEi/BBs. In unadjusted analysis, White women (vs. Black) (OR 0.33, 95% 0.19-0.58) and women with higher ratings of functional wellbeing (OR 0.94, 95% 0.89-0.99) were less likely to use ACEi/BBs. Satisfaction with provider communication was only significant for White women. In multivariable-adjusted analysis, ACEi/BB use did not differ by race. Correlates of ACEi/BB use included hypertension among all women and older age for Black women only. CONCLUSIONS: After adjusting for age and comorbidities, no differences by race in ACEi/BB use were observed. Hypertension was a major contributor of ACEi/BB use in BC survivors.
Authors: Mirjam E Mast; Mark W Heijenbrok; Anna L Petoukhova; Astrid N Scholten; Joop H M Schreur; Henk Struikmans Journal: Int J Radiat Oncol Biol Phys Date: 2011-12-03 Impact factor: 7.038
Authors: Daniel de Araujo Brito Buttros; Mauro Terra Branco; Claudio Lera Orsatti; Benedito de Sousa Almeida-Filho; Jorge Nahas-Neto; Eliana A P Nahas Journal: Menopause Date: 2019-09 Impact factor: 2.953
Authors: Annelies H Boekhout; Jourik A Gietema; Bojana Milojkovic Kerklaan; Erik D van Werkhoven; Renske Altena; Aafke Honkoop; Maartje Los; Willem M Smit; Peter Nieboer; Carolien H Smorenburg; Caroline M P W Mandigers; Agnes J van der Wouw; Lonneke Kessels; Annette W G van der Velden; Petronella B Ottevanger; Tineke Smilde; Jaap de Boer; Dirk J van Veldhuisen; Ido P Kema; Elisabeth G E de Vries; Jan H M Schellens Journal: JAMA Oncol Date: 2016-08-01 Impact factor: 31.777
Authors: Jennifer L Patnaik; Tim Byers; Carolyn DiGuiseppi; Dana Dabelea; Thomas D Denberg Journal: Breast Cancer Res Date: 2011-06-20 Impact factor: 6.466
Authors: Sofie A M Gernaat; Jolanda M A Boer; Desiree H J van den Bongard; Angela H E M Maas; Carmen C van der Pol; Rhodé M Bijlsma; Diederick E Grobbee; Helena M Verkooijen; Petra H Peeters Journal: Breast Cancer Res Treat Date: 2018-02-28 Impact factor: 4.872